申请人:SMITHKLINE BECKMAN CORPORATION
公开号:EP0168950A1
公开(公告)日:1986-01-22
Compounds of formula
in which,
X1 is C2-6 alkyl, (CH3)2C=CHCH2 or phenyl;
X2 and X3 are each hydrogen or, when X1 is C2-6 alkyl,
X2 and X3 together can also form a carbon atom bond; Y is selected from the group consisting of -C02H, -CH2OH, CHCH20H and -CH(CH2)nC02H wherein n is 2 or 3 and Z is OH Z hydroxyl or hydrogen; and R is selected from the imidazolyl radical of the following formulae (A) or (B)
wherein R1 is hydrogen, C1 to C4 alkyl or C3 to C4 alkenyl, R2 is hydrogen, C1 to C4 alkyl, carboxyl or carboxamido, or either -(CH2)pCO2H or -(CH2)pCONH2,
wherein p is 1 ro 2, when R1 and R3 are hydrogen or C1 to C4 alkyl, and R3 is hydrogen, C1 to C4 alkyl or -CH2CO2H with the proviso that R1, R2 and R3 cannot all be hydrogen or
wherein R4 is hydrogen, C1 to C4 alkyl or C3 to C4 alkenyl, R5 is hydrogen, C1 to C4 alkyl or C3 to C4 alkenyl and R6 is hydrogen or carboxyl with the proviso that R4, R5 and R6 cannot all be hydrogen; or a pharmaceutically acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases in which leukotrienes are a factor e.g. asthma.
式的化合物
其中
X1 是 C2-6 烷基、(CH3)2C=CHCH2 或苯基;
X2 和 X3 各为氢,或当 X1 为 C2-6 烷基时、
X2 和 X3 也可以一起形成碳原子键;Y 选自-C02H、-CH2OH、CHCH20H 和-CH(CH2)nC02H 所组成的组,其中 n 为 2 或 3,Z 为羟基 OH 或氢;R 选自下式(A)或(B)的咪唑基
其中 R1 为氢、C1 至 C4 烷基或 C3 至 C4 烯基,R2 为氢、C1 至 C4 烷基、羧基或羧酰胺基,或-(CH2)pCO2H 或-(CH2)pCONH2、
其中 p 为 1 ro 2,当 R1 和 R3 为氢或 C1 至 C4 烷基时,R3 为氢、C1 至 C4 烷基或-CH2CO2H,但 R1、R2 和 R3 不能都是氢或 C1 至 C4 烷基。
其中 R4 是氢、C1 至 C4 烷基或 C3 至 C4 烯基,R5 是氢、C1 至 C4 烷基或 C3 至 C4 烯基,R6 是氢或羧基,但 R4、R5 和 R6 不能都是氢;或它们的药学上可接受的盐;它们的制备工艺,含有它们的药物组合物,以及它们在治疗白三烯是一个因素的疾病如哮喘中的用途。